



The Huningue Biotechnology Centre

1st manufacturing site for monoclonal antibodies in France

Launched in 2005 and expanded in 2020, the Huningue site produces the drug substance for 4 major biomedicines in different therapeutic areas.

These innovative treatments can significantly improve the daily lives of patients. The Huningue site is approved by health authorities (including the FDA) and has Quality and Manufacturing Science & Technology laboratories.

“At Novartis, we are imagining the medicine of tomorrow to improve and extend patients’ lives. At the Huningue site, our teams are committed every day for patients. Quality and safety are at the heart of our mission. We foster a culture in which every associate feels good, empowered, and proud of the “Made in Huningue”.

We are constantly looking for opportunities to develop our teams, invest in new technologies and further optimize our processes.”

Imre Bajusz,
Huningue Site Head



OUR COMMITMENTS

Ensure continuous, reliable and competitive production of biologics to meet the global needs of patients.

Strive for high targets in terms of security, quality and transparency in all our activities.

Limit our environmental footprint with significant improvements in carbon emissions, waste management and water consumption.

KEY INFO

A continuous production **24/7** with a capacity of **+120K L** of cell culture producing the equivalent of **20M doses per year** for patients around the world thanks to **+700 associates** and state-of-the-art facilities.



For more information,
scan this code.

Find our job offers on
www.novartis.com/careers